Zimmer Biomet (NYSE:ZBH) Insider Sells $528,978.45 in Stock

Key Points

• Insider sale: Zimmer Biomet insider Kevin Thornal sold 5,691 shares for approximately $528,978 at an average price of $92.95.
• Financial performance: The company exceeded quarterly earnings and revenue expectations, reporting adjusted EPS of $2.07 and revenue of $2.18 billion, with revenue up 4.8% year over year.
• Market outlook: Analysts maintain a consensus “Hold” rating with an average price target of $104.42, while Zimmer Biomet declared a quarterly dividend of $0.24 per share, yielding about 1.0% annually.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Get Free Report) insider Kevin Thornal sold 5,691 shares of the firm's stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $92.95, for a total value of $528,978.45. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Zimmer Biomet Stock Performance

ZBH traded up $1.91 during trading on Tuesday, hitting $98.45. 3,615,966 shares of the stock were exchanged, compared to its average volume of 2,264,630. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50. Zimmer Biomet Holdings, Inc. has a 1-year low of $79.12 and a 1-year high of $106.88. The stock has a fifty day moving average price of $95.68 and a two-hundred day moving average price of $91.45. The firm has a market capitalization of $18.78 billion, a P/E ratio of 23.95, a PEG ratio of 1.76 and a beta of 0.47.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The business had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.13 billion. During the same period in the prior year, the company earned $2.07 earnings per share. The company's revenue was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.54 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a $0.24 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. Zimmer Biomet's payout ratio is currently 23.36%.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on ZBH shares. Canaccord Genuity Group raised their price target on Zimmer Biomet from $83.00 to $100.00 and gave the stock a "hold" rating in a report on Monday, August 10th. Needham & Company LLC reaffirmed a "hold" rating on shares of Zimmer Biomet in a report on Wednesday, August 5th. Citigroup cut their price target on shares of Zimmer Biomet from $95.00 to $93.00 and set a "neutral" rating for the company in a report on Thursday, May 28th. Royal Bank Of Canada lifted their price objective on Zimmer Biomet from $101.00 to $110.00 and gave the company an "outperform" rating in a report on Thursday, August 6th. Finally, Truist Financial increased their target price on Zimmer Biomet from $92.00 to $106.00 and gave the stock a "hold" rating in a research note on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $104.42.

Institutional Trading of Zimmer Biomet

Institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new position in Zimmer Biomet in the second quarter valued at about $1,344,282,000. Franklin Resources Inc. grew its position in Zimmer Biomet by 43.2% in the fourth quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider's stock valued at $601,204,000 after acquiring an additional 2,017,857 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Zimmer Biomet by 0.7% during the fourth quarter. Geode Capital Management LLC now owns 5,233,834 shares of the medical equipment provider's stock valued at $468,821,000 after purchasing an additional 36,611 shares during the period. Primecap Management Co. CA acquired a new position in shares of Zimmer Biomet during the second quarter worth $328,578,000. Finally, Van ECK Associates Corp lifted its position in shares of Zimmer Biomet by 3.9% during the fourth quarter. Van ECK Associates Corp now owns 3,613,425 shares of the medical equipment provider's stock worth $324,920,000 after purchasing an additional 136,519 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company's stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc NYSE: ZBH is a medical technology company that develops, manufactures and markets products designed to treat musculoskeletal conditions. Its portfolio includes orthopedic implants and related systems for hip, knee, shoulder and other joint replacements, as well as products used in sports medicine, extremity care and trauma procedures.

The company also provides robotic- and computer-assisted surgical technologies, digital solutions and other tools intended to support orthopedic procedures and patient care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.